greeksoup/ stock research

Elanco Animal Health (ELAN) Q2 FY2026 earnings: revenue $1.4 billion, up 10.2% on the year

Elanco Animal Health Inc. (ELAN) reported revenue of $1.4 billion for Q2 FY2026, the quarter ended 30 June 2026, up 10.2% on the same quarter a year earlier. Net income was $54 million, up 390.9% on the year, and diluted earnings per share $0.11. The figures are the company's own, from the 10-Q it filed with the SEC on 5 August 2026.

Revenue$1.4 billionup 10.2%
Net income$54 millionup 390.9%
Diluted EPS$0.11
QuarterQ2 FY2026ended 30 June 2026

The quarter, against the one before and a year earlier

LineQ2 FY2026Q1 FY2026Q2 FY2025Change on the year
Revenue1,3681,3711,241+10.2%
Cost of revenue570586528+8.0%
Gross profit798785713+11.9%
Gross margin58.3%57.3%57.5%
Research and development92.097.092.0+0.0%
Selling, general and administrative449381400+12.2%
Pre-tax income56.087.025.0+124.0%
Income tax2.030.014.0-85.7%
Effective tax rate3.6%34.5%56.0%
Net income54.057.011.0+390.9%
Net margin3.9%4.2%0.9%
Diluted EPS$0.11$0.11$0.02+450.0%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ2 FY2026Q1 FY2026Q2 FY2025Change on the year
Operating cash flow27713.0237+16.9%
Capital expenditure33.051.057.0-42.1%
Free cash flow244-38.0180+35.6%
Free cash flow margin17.8%-2.8%14.5%
Cash from investing-110-60.0-56.0n/a
Cash from financing-74.0-65.0-156n/a
Depreciation and amortisation165172161+2.5%
Share-based compensation20.021.020.0+0.0%
Diluted shares, weighted506m506m500m+1.2%
Shares outstanding at period end500m499m497m+0.6%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ2 FY2026Q1 FY2026Q2 FY2025Change on the year
Shareholders' equity6,5886,5006,775-2.8%
Debt3,6633,7363,954-7.4%
Other liabilities3,3102,9863,013+9.9%
Total liabilities and equity13,56113,22213,742-1.3%
Fixed assets1,4111,3951,357+4.0%
Goodwill4,8454,7234,758+1.8%
Intangible assets3,2043,2253,705-13.5%
Cash and equivalents530428539-1.7%
Receivables1,0771,084989+8.9%
Inventory1,7691,7171,670+5.9%
Other assets725650724+0.1%
Total assets13,56113,22213,742-1.3%

Quarterly results, the last 12 quarters

Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue1,0681,0351,2051,1841,0301,0201,1931,2411,1371,1441,3711,368
Cost of revenue487516515495492501509528530555586570
Gross profit581519690689538519684713607589785798
Gross margin54%50%57%58%52%51%57%57%53%51%57%58%
R&D86.079.087.089.087.081.094.092.089.093.097.092.0
SG&A313292337354323300341400351338381449
Operating income-1,097-12712.0-32.0559-51.0n/an/an/an/an/an/a
Operating margin-103%-12%1%-3%54%-5%n/an/an/an/an/an/a
Interest expense72.067.066.065.058.0n/an/an/an/an/an/an/a
Pre-tax income-1,097-12712.0-32.0559-51.060.025.0-50.0-25987.056.0
Tax raten/an/a-167%n/a35%n/a-12%56%n/an/a34%4%
Net income-1,096-14132.0-50.0364-8.067.011.0-34.0-27657.054.0
Net margin-103%-14%3%-4%35%-1%6%1%-3%-24%4%4%
Diluted EPS-$2.22-$0.29$0.06-$0.10$0.73-$0.02$0.13$0.02-$0.07-$0.56$0.11$0.11
Operating cash flow1981572.0200162177-4.023721910813.0277
Capital expenditure33.041.024.034.042.047.065.057.092.062.051.033.0
Free cash flow165116-22.0166120130-69.018012746.0-38.0244
Shares outstanding493m493m494m494m494m494m496m497m497m497m499m500m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS and diluted share count are from the company's results press release for that quarter, used where the release gives the same revenue and net income as the table. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 30 June 2026, filed 5 August 2026, accession 0001739104-26-000043: the filing on EDGAR. All of Elanco Animal Health Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install